Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 10—October 2004
Dispatch

Arcobacter Species in Humans1

Olivier Vandenberg*†Comments to Author , Anne Dediste*, Kurt Houf‡, Sandra Ibekwem§, Hichem Souayah*, Sammy Cadranel¶, Nicole Douat#, G. Zissis*, J.-P. Butzler§, and P. Vandamme‡
Author affiliations: *Saint-Pierre University Hospital, Brussels, Belgium; †Free University of Brussels, Brussels, Belgium; ‡Ghent University, Ghent, Belgium; §Vrije Universiteit Brussel, Brussels, Belgium; ¶Queen Fabiola University Hospital, Brussels, Belgium; #Brugmann University Hospital, Brussels, Belgium; **Queen Fabiola University Hospital, Brussels, Belgium

Main Article

Table 2

Case-control study of microbiologic and clinical features of patients with Arcobacter butzleri and Campylobacter jejuni infection

Features/treatment/outcome No. patients with 
A. butzleri infection (%) No. patients with 
C. jejuni infection (%) OR (95% CI)
Microbiologic features
  Erythrocytes in stool 4/67 (6.0) 59/201 (29.4) 0.15 (0.05–0.46)
  Leukocytes in stool 2/67 (3.0) 36/201 (17.9) 0.14 (0.02–0.62)
  Associated organisms 12/67 (17.9) 24/201 (11.9) 1.61 (0.71–3.63)
Clinical features
  Diarrhea 41/61 (67.2) 149/191 (78.0) 0.58 (0.29–1.14)
  Acute diarrhea 31/61 (50.8) 140/191 (73.3) 0.38 (0.20–0.79)
  Persistent diarrhea 10/61 (16.4) 9/191 (4.7) 3.97 (1.40–11.33)
  Watery diarrhea 31/61 (50.8) 61/191 (31.9) 2.20 (1.18–4.13)
  Fever, temperature >38.5°C 20/61 (32.8) 83/191 (43.5) 0.63 (0.33–1.21)
  Nausea, vomiting, or both 17/61 (27.9) 47/191 (24.6) 1.18 (0.59–2.37)
  Abdominal pain 18/61 (29.5) 53/191 (27.7) 1.09 (0.55–2.15)
  Asymptomatic carriage 12/61 (19.7) 19/191 (9.9) 2.22 (0.94–5.21)
  Underlying disease 10/61 (16.4) 49/191 (25.7) 0.57 (0.25–1.27)
Treatment
  Antimicrobial agents 16/61 (26.2) 79/191 (41.4) 0.50 (0.25–1.00)
  Intravenous fluid therapy 1/61 (1.6) 8/191 (4.2) 0.38 (0.38–3.05)
Outcome
  Relapse 4/61 (6.6) 6/191 (3.1) 2.16 (0.49–9.06)

aOR, odds ratio; CI, confidence interval.

Main Article

1Presented in part at the 11th International Congress on Infectious Diseases, Cancun, Mexico, Mar 4–8, 2004. (Abstract P09.030); and at the 12th International Workshop on Campylobacter, Helicobacter and Related Organisms. Aarhus, Denmark, Sept 6–10, 2003 (Abstract K-07).

Page created: April 11, 2011
Page updated: April 11, 2011
Page reviewed: April 11, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external